Company intelligence / Profile preview

Empire Genomics

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

Empire Genomics provides commercialized FISH and CISH probes for clinical diagnostics and research. Their products enable detection of genetic abnormalities critical in oncology and other disease areas. They have rapid turnaround times for both catalogued and custom probes.

Therapeutic areas: OncologyRare Diseases
Modalities: Diagnostic probeCustom assay development
Industry: Molecular Diagnostics

Partnerships

BioDot

Beyond the preview

Go deeper on Empire Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Empire Genomics.

Explore the full profile